What this evidence supports
ARPA-H describes ADVOCATE as a program intended to develop clinical AI agents for cardiovascular-care tasks together with a supervisory AI component for post-deployment monitoring.
What it does not establish
The solicitation submission window closed April 1, 2026. The program objective remains prospective and does not establish a selected performer, deployed system, clinical validation, FDA authorization, effect, or result.
Answer-ready summary
ADVOCATE's clinical-agent and supervisory-monitoring objective remains prospective; its solicitation submission window closed April 1, 2026, and no validation, authorization, or result is reported.
Record details
- Decision priority
- Watch
- Current status
- Program objective remains prospective · solicitation submission window closed 2026-04-01 · no validation, authorization, or results reported
- Evidence tracks
- Technologies/care models · Interventions
- Source authority
- Primary/authoritative
- Source organization
- ARPA-H
- Evidence design
- Federal R&D program
- Applicability
- Applicable to decisions about the stated program, policy, standard, or development context; not evidence of clinical benefit beyond the cited scope.
- Confidence for the stated claim
- High
- Freshness
- Changed
- Record date
- 2026-01-13
- Source date (official launch release)
- 2026-01-13
- Last verified
- 2026-09-03
- Review due
- 2026-10-03 or sooner if the cited source changes.
- Version
- 1.1
- Revision state
- Version 1.1 recasts ADVOCATE as a prospective program objective, records the April 1, 2026 solicitation closure and no-results boundary, adds the official launch source, and records the September 3, 2026 re-verification.
Evidence record fields
- Claim supported
- ARPA-H describes ADVOCATE as a program intended to develop clinical AI agents for cardiovascular-care tasks together with a supervisory AI component for post-deployment monitoring.
- Source type and design
- Federal R&D program
- Population and setting
- Not a participant-level clinical-study population in this source type. The program, policy, regulatory, standards, or research context described by the cited source.
- Intervention/exposure and comparator
- Not evaluated as a comparative intervention or exposure in the cited administrative or program source. No comparator is reported for this source-bounded claim.
- Outcome or endpoint
- The program, policy, regulatory, standards, or development state stated in the claim supported; no clinical outcome is inferred.
- Follow-up duration
- No clinical follow-up duration is reported for this source-bounded claim.
- Effect estimate and uncertainty
- No clinical effect estimate is reported. No statistical uncertainty estimate is reported; uncertainty is bounded through the source scope and stated limitations.
- Harms/adverse events
- No harms or adverse-event analysis is reported for this source-bounded administrative or program claim.
- Missing data and attrition
- Not reported; this record does not analyze participant-level data. Not applicable or not reported; no longitudinal participant cohort is analyzed.
- Bias/limitations
- The solicitation submission window closed April 1, 2026. The program objective remains prospective and does not establish a selected performer, deployed system, clinical validation, FDA authorization, effect, or result.
- Applicability/generalizability
- Applicable to decisions about the stated program, policy, standard, or development context; not evidence of clinical benefit beyond the cited scope.
- Funding/conflicts
- Funding or sponsorship is recorded only where the cited source and claim state it; otherwise it is not assessed in this record. No conflict-of-interest assessment is reported for this administrative or program-source record.
- Replication or corroboration
- The administrative or program claim is anchored to the cited authoritative source; independent clinical replication is not implied.
- Decision use
- Use as source-bounded context for Researchers, Innovators, Funders/investors, Policymakers, Clinicians; do not use as stand-alone evidence of safety, efficacy, coverage, endorsement, or scaled adoption.
- Last reviewed / review due
- Last reviewed 2026-09-03; review due 2026-10-03 or sooner if the cited source changes.
For this decision
Researchers · Innovators · Funders/investors · Policymakers · Clinicians